AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results
– Total 2021 Net Revenue of
– FOTIVDA® (tivozanib)
– FOTIVDA
– Full Year 2022 FOTIVDA
– Long-term data from pivotal TIVO-3 study presented at ASCO GU 2022 continue to demonstrate durable disease control and positive trend for overall survival for FOTIVDA –
– Company to Host Conference Call Today at
“We have seen quarter over quarter growth in FOTIVDA® (tivozanib) sales since its commercial launch on
“Our clinical team continues to make steady progress with expanding the opportunities for FOTIVDA in an effort to move to earlier settings in combinations with novel therapies as well as advancing our pipeline of monoclonal antibodies that collectively we believe will build long-term value for our shareholders.”
Fourth Quarter 2021 and Recent Highlights
- Ended 2021 with quarter over quarter growth of FOTIVDA net sales and prescriptions heading into 2022
- Fourth quarter 2021 U.S. net product revenue increased 17% from
$14 .3 millionU.S. net product revenue in the third quarter of 2021 to$16.8 million , which reflects inventory shipped to distributors and a gross-to-net estimate of 14% during the fourth quarter. As ofDecember 31, 2021 ,U.S. net product revenue since FOTIVDA’s commercial launch onMarch 22, 2021 was$38.9 million , which reflects a gross-to-net-estimate of 15% for the year.- 780 commercial prescriptions filled in the fourth quarter of 2021, representing a 26% increase from 619 commercial prescriptions filled in the third quarter of 2021.
- FOTIVDA took the leadership position in the share of third-line RCC new patient starts in
December 2021 , which continued through the latestJanuary 2022 data, as reported in IQVIA's BrandImpact report. This report suggests FOTIVDA is being more broadly adopted in the earlier third-line setting, which may result in an increase in the average treatment duration over time.- AVEO Specialty Pharmacy Sales Data demonstrated that the rate of early discontinuations decreased in the fourth quarter as utilization moves to earlier lines of therapy.
- AVEO Specialty Pharmacy Sales Data demonstrated that the rate of early discontinuations decreased in the fourth quarter as utilization moves to earlier lines of therapy.
- Fourth quarter 2021 U.S. net product revenue increased 17% from
- Positive new five year follow-up data for PFS from the Phase 3 TIVO-3 Clinical Trial of tivozanib in R/R advanced RCC patients were presented at the 2022 ASCO GU Cancers Symposium.
- These new long-term PFS data from patients with five years of follow up further support the durable response and improved PFS previously observed in patients treated with FOTIVDA, including:
- Landmark long-term PFS rates were consistently higher among patients treated with FOTIVDA as compared to patients treated with sorafenib (12% vs. 2% and 7.6% vs. 0% at three and four years, respectively), representing a clinically meaningful outcome for patients in the third- and fourth-line treatment setting.
- Long-term overall survival (OS) was also analyzed and a non-significant trend favoring FOTIVDA continued to emerge with accumulation of events (HR 0.89).
- These new long-term PFS data from patients with five years of follow up further support the durable response and improved PFS previously observed in patients treated with FOTIVDA, including:
- Topline data for first-line cohort of the DEDUCTIVE trial were presented at the 2022
American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium.
- New efficacy and safety data from the first line (cohort A) of the Phase 1b/2 clinical trial of tivozanib in combination with AstraZeneca’s IMFINZI® (durvalumab) demonstrated a 28% partial response (PR) rate and disease control rate of 72% (PR plus stable disease) with a median PFS of 7.3 months and a 1-year OS of 76%. The data continues to support the efficacy and safety of tivozanib as an attractive vascular endothelial growth factor receptor inhibitor to use in combination with immune checkpoint inhibitors in first line metastatic hepatocellular carcinoma (HCC) patients.
- The DEDUCTIVE trial is currently enrolling cohort B of second line patients after treatment with bevacizumab and atezolizumab. This cohort, which will enroll up to 20 subjects, has the potential to be the first clinical study to demonstrate benefit in the emerging population of HCC patients who have previously received immunotherapy.
- Initiated Pivotal Phase 3 TiNivo-2 Trial in Advanced Refractory RCC following Prior Immunotherapy.
- AVEO initiated the Phase 3 TiNivo-2 clinical trial evaluating tivozanib in combination with nivolumab (OPDIVO®), Bristol Myers Squibb’s antibody directed against programmed death-1, in patients with advanced refractory RCC following one or two lines of therapy, one of which must be an immunotherapy. If successful, this trial has the potential to significantly expand the market opportunity for FOTIVDA in the larger second line RCC setting. Bristol Myers Squibb is providing nivolumab clinical drug supply pursuant to a clinical trial collaboration and supply agreement. We expect TiNivo-2 enrollment to be completed in the first half of 2023.
- Entered clinical development collaboration with
NiKang Therapeutics, Inc. (NiKang) to evaluate the combination of NKT2152 (HIF2α) and tivozanib to treat advanced RCC.
- AVEO entered into a clinical trial collaboration and supply agreement with NiKang to evaluate NKT2152, NiKang’s hypoxia inducible factor 2α (HIF2α), in combination with tivozanib in RCC patients who have not responded to or relapsed from prior therapies. AVEO anticipates the Phase 2 clinical trial to evaluate the combination is expected to commence in 2022.
- Entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt,
Germany to evaluate ficlatuzumab in combination with ERBITUX® (cetuximab) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
- This combination therapy has demonstrated the potential to play a meaningful part in the treatment of patients with human papillomavirus (HPV) negative R/M HNSCC, which is the majority of the patient population and is typically associated with particularly poorer patient outcomes. AVEO will serve as the trial sponsor and will be responsible for costs associated with the execution of the trial.
- AVEO has started scale up activities for the manufacturing of ficlatuzumab clinical supply in the second quarter of 2022 to enable the initiation of a potential registrational clinical trial in HPV negative R/M HNSCC in the first half of 2023. AVEO expects to continue to discuss potential ficlatuzumab pivotal clinical trial designs with the
U.S. Food and Drug Administration (FDA) and to continue to seek a strategic partner. InSeptember 2021 , AVEO announced that the FDA granted Fast Track designation for the investigation of the combination of ficlatuzumab and cetuximab for the treatment of patients with R/R HNSCC.
- Update on Phase 1 clinical trial of AV-380.
- The last patient was dosed in the Phase 1 healthy subject clinical trial of AV-380.
- Initial data observed a reduction of GDF15 in subjects and no drug related adverse events were identified. However, operational errors at the trial site have caused data integrity concerns and AVEO has notified the FDA to confirm the suitability of the data for regulatory purposes and whether AVEO may publish the data from this trial. AVEO does not expect that the data quality issues in the Phase 1 clinical trial will impact its plans to initiate a Phase 1b clinical trial in cancer patients in the second half of 2022.
- Jeb Ledell Appointed as Chief Operating Officer.
- AVEO appointed
Mr. Ledell as Chief Operating Officer inDecember 2021 , where he is responsible for overseeing operational functions key to maximizing AVEO’s organizational efficiency and advancing its pipeline of products.Mr. Ledell joins AVEO from Enzyvant Therapeutics, where he served as chief operating officer and led key business operations during the recent FDA approval of RETHYMIC®. Prior to joining Enzyvant Therapeutics,Mr. Ledell served as the chief operating officer at Compass Therapeutics andHorizon Discovery Group , during which time he led operations at both organizations through several changes in scale.
- AVEO appointed
- Additional
$5.0 million made available to AVEO under its Loan Facility with Hercules Capital, Inc. (Hercules) and its affiliates.
- In late
December 2021 , AVEO achieved sales Performance Milestone II of$35.0 million in net product revenues from sales of FOTIVDA ahead of theApril 1, 2022 deadline. Following satisfaction of Performance Milestone II, AVEO drew down the additional$5.0 million tranche in 2021.
- In late
- Entered Preclinical Research Collaboration with Actinium Pharmaceuticals, Inc. (Actinium) to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors.
- In
February 2022 , AVEO entered into a research collaboration to develop and study a first-in-class antibody radio-conjugate (ARC) targeting ErbB3, also known as HER3. Actinium will utilize its Antibody Warhead Enabling technology platform and extensive radiotherapy know-how to conjugate one of AVEO's ErbB3 targeted antibodies with Actinium-225, a potent alpha-emitting radioisotope, to form a novel Ac-225 ErbB3 targeted radiotherapy.
- In
Fourth Quarter and Year End 2021 Financial Highlights
- At
December 31, 2021 , AVEO reported$87 .3 million in cash, cash equivalents and marketable securities, as compared with$61 .8 million atDecember 31, 2020 . - Total revenue for the fourth quarter of 2021 was approximately
$17 .6 million compared with$0 .9 million for the fourth quarter of 2020. Total revenue for full year 2021 was approximately$42 .3 million compared to$6 .0 million for full year 2020. - FOTIVDA
U.S. net product revenue was$16 .8 million and$38 .9 million for the fourth quarter and full year 2021, respectively. - Research and development expense for the fourth quarter of 2021 was
$6.1 million compared with$4.6 million for the fourth quarter of 2020. Research and development expense for the full year 2021 was$26 .3 million compared with$22 .7 million for the full year 2020. - Selling, general and administrative expense for the fourth quarter of 2021 was
$15 .7 million compared with$9 .0 million for the fourth quarter of 2020. Selling, general and administrative expense for the full year 2021 was$60 .8 million compared with$22 .2 million for the full year 2020. The increase in selling, general and administrative expense for the fourth quarter and full year 2021 is primarily due to costs associated with the commercial launch of FOTIVDA. - Net loss for the fourth quarter of 2021 was
$7 .3 million, or net loss of$0.21 per basic and diluted share, compared with a net loss of$11 .5 million for the fourth quarter of 2020, or net loss of$0.44 per basic and diluted share. - Net loss for the full year 2021 was
$53 .3 million, or net loss of$1.63 per basic and diluted share, compared with a net loss of$35 .6 million for the full year 2020, or net loss of$1.66 per basic and diluted share.
Financial Guidance
AVEO believes that its
AVEO currently expects to achieve full year 2022 FOTIVDA
Conference Call and Webcast
In connection with this announcement, AVEO will host a conference call and audio webcast today,
About FOTIVDA® (tivozanib)
FOTIVDA® (tivozanib) is an oral, next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. AVEO received
INDICATIONS
FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Hypertension and Hypertensive Crisis: Control blood pressure prior to initiating FOTIVDA. Monitor for hypertension and treat as needed. For persistent hypertension despite use of anti-hypertensive medications, reduce the FOTIVDA dose.
Cardiac Failure: Monitor for signs or symptoms of cardiac failure throughout treatment with FOTIVDA.
Cardiac Ischemia and Arterial Thromboembolic Events: Closely monitor patients who are at increased risk for these events. Permanently discontinue FOTIVDA for severe arterial thromboembolic events, such as myocardial infarction and stroke.
Venous Thromboembolic Events: Closely monitor patients who are at increased risk for these events. Permanently discontinue FOTIVDA for severe venous thromboembolic events.
Hemorrhagic Events: Closely monitor patients who are at risk for or who have a history of bleeding.
Proteinuria: Monitor throughout treatment with FOTIVDA. For moderate to severe proteinuria, reduce the dose or temporarily interrupt treatment with FOTIVDA.
Thyroid Dysfunction: Monitor before initiation and throughout treatment with FOTIVDA.
Risk of Impaired Wound Healing: Withhold FOTIVDA for at least 24 days before elective surgery. Do not administer for at least 2 weeks following major surgery and adequate wound healing. The safety of resumption of FOTIVDA after resolution of wound healing complications has not been established.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Discontinue FOTIVDA if signs or symptoms of RPLS occur.
Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception.
Allergic Reactions to Tartrazine: The 0.89 mg capsule of FOTIVDA contains FD&C Yellow No.5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible patients.
ADVERSE REACTIONS
The most common (≥20%) adverse reactions were fatigue, hypertension, diarrhea, decreased appetite, nausea, dysphonia, hypothyroidism, cough, and stomatitis, and the most common Grade 3 or 4 laboratory abnormalities (≥5%) were sodium decreased, lipase increased, and phosphate decreased.
DRUG INTERACTIONS
Strong CYP3A4 Inducers: Avoid coadministration of FOTIVDA with strong CYP3A4 inducers.
USE IN SPECIFIC POPULATIONS
Lactation: Advise not to breastfeed.
Females and Males of Reproductive Potential: Can impair fertility.
Hepatic Impairment: Adjust dosage in patients with moderate hepatic impairment. Avoid use in patients with severe hepatic impairment.
To report SUSPECTED ADVERSE REACTIONS, contact
Please see FOTIVDA Full Prescribing Information which is available at www.FOTIVDA.com.
About Advanced Renal Cell Carcinoma
According to the American Cancer Society’s 2021 statistics, renal cell carcinoma (RCC) is the most common type of kidney cancer, which is among the ten most common cancers in both men and women. Approximately 73,750 new cases of kidney cancer will be diagnosed annually and about 14,830 people will die from this disease. In patients with late-stage disease, the five-year survival rate is 13%. Agents that target the vascular endothelial growth factor (VEGF) pathway have shown significant antitumor activity in RCC.2 According to a 2019 publication, 50% of the approximately 10,000 patients who progress following two or more lines of therapy choose not to receive further treatment,3 which may be attributable to tolerability concerns and a lack of data to support evidence-based treatment decisions in this highly relapsed or refractory patient population.
About
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. The words “anticipate,” “believe,” “design,” “expect,” “hope,” “intend,” “may,” “plan,” “potential,” “could,” “should,” “would,” “seek,” “look forward,” “advance,” “goal,” “strategy,” or the negative of these terms or other similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about: AVEO’s expectations of achieving quarter over quarter sales growth and an increase in its sales ramp of FOTIVDA in future periods; AVEO’s, plans, strategies ability to successfully sell and distribute FOTIVDA to patients in
Any reference to AVEO’s website address in this press release is intended to be an inactive textual reference only and not an active hyperlink.
References
- Pawlowski N et al. AACR 2013. Poster 3971.
- J Angulo and O Shapiro, Cancers (
Basel ) 2019 Sep; 11(9): 1227. [10.3390/cancers11091227] Decision Resources . RCC landscape and forecast.December 12, 2019 .
Consolidated Statements of Operations
(In thousands, except per share amounts)
Years Ended |
Three Months Ended |
||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||
Revenues: | |||||||||||||||
FOTIVDA |
$ | 38,874 | $ | — | $ | 16,755 | $ | — | |||||||
Partnership licensing and royalty revenue | 3,421 | 6,019 | 891 | 886 | |||||||||||
42,295 | 6,019 | 17,646 | 886 | ||||||||||||
Operating expenses: | |||||||||||||||
Cost of products sold | 4,737 | — | 2,033 | — | |||||||||||
Research and development | 26,298 | 22,679 | 6,121 | 4,574 | |||||||||||
Selling, general and administrative | 60,814 | 22,217 | 15,652 | 9,008 | |||||||||||
91,849 | 44,896 | 23,806 | 13,582 | ||||||||||||
Loss from operations | (49,554 | ) | (38,877 | ) | (6,160 | ) | (12,696 | ) | |||||||
Other income (expense), net: | |||||||||||||||
Interest expense, net | (4,045 | ) | (1,605 | ) | (1,153 | ) | (522 | ) | |||||||
Other income | 58 | — | 58 | — | |||||||||||
Change in fair value of PIPE Warrant liability | 199 | 4,898 | — | 1,714 | |||||||||||
(3,788 | ) | 3,293 | (1,095 | ) | 1,192 | ||||||||||
Net income (loss) | $ | (53,342 | ) | $ | (35,584 | ) | $ | (7,255 | ) | $ | (11,504 | ) | |||
Net income (loss) per share | $ | (1.63 | ) | $ | (1.66 | ) | $ | (0.21 | ) | $ | (0.44 | ) | |||
Weighted average number of common shares outstanding | 32,661 | 21,402 | 34,384 | 26,252 |
Consolidated Balance Sheet Data
(In thousands)
2021 |
2020 |
||||
Assets | |||||
Cash, cash equivalents and marketable securities | $ | 87,326 | $ | 61,761 | |
Trade receivables, net and partnership receivables | 11,601 | 1,197 | |||
Inventory | 1,656 | — | |||
Prepaid expenses and other current assets | 4,153 | 2,550 | |||
Property and equipment, net | 276 | 343 | |||
Operating lease right-of-use asset | 178 | 903 | |||
Other assets | 151 | 158 | |||
Total assets | $ | 105,341 | $ | 66,912 | |
Liabilities and stockholders’ equity | |||||
Accounts payable and accrued expenses | $ | 18,142 | $ | 12,393 | |
Loans payable, net of discount | 37,960 | 13,772 | |||
Deferred revenue and research and development reimbursements | 578 | 2,716 | |||
PIPE Warrant liability | — | 199 | |||
Operating lease liability | 11 | 705 | |||
Other liabilities | 2,780 | 1,833 | |||
Stockholder’s equity | 45,870 | 35,294 | |||
Total liabilities and stockholders’ equity | $ | 105,341 | $ | 66,912 |
AVEO Investor Relations Contact:
(617) 430-7578
hans@lifesciadvisors.com

Source: AVEO Pharmaceuticals, Inc.